Back to search

University of Crete (UOC)

Ο ρόλος των miRNAs που ενέχονται στη ρύθμιση της ανοσολογικής απάντησης στην εκτίμηση της έκβασης ασθενών με καρκίνο μαστού

Abstract

dc:description

The role of miRNAs that are involved in regulating the immune response to the assessment of the clinical outcome of patients with breast cancer. 1. Introduction: Breast cancer (BC) is the leading cause of cancer-related morbidity and 2nd cause of death among women. Following surgical excision, women with early breast cancer receive adjuvant systemic therapy with or without local radiotherapy, but despite treatment, a significant proportion of them will develop metastases, which is the main cause of death. The immunoediting concept, which describes the dynamic relation between cancer and the immune system, is based on three stages: elimination, equilibrium, and escape. The elimination phase refers to the attack of innate and adaptive immune cell types to eradicate cancer cells; cancer cells that survived immune destruction may then enter the equilibrium phase where immunoediting occurs. The escape phase represents the final phase of the process, where immunologically shaped tumors may grow aggressively, become clinically apparent, and establish an immunosuppressive tumor microenvironment ultimately leading to tumor progression. In all three stages, various immune cell subsets, cytokines, micro-RNAs (miRs), exosomes, and cancer cells have been shown top articipate in the process. MicroRNAs (miRNAs), a class of small non-coding RNA of approximately 20–22 nucleotides in length, play a significant role in the regulation of gene transcription, by binding to the 3ʹuntranslated region of the target mRNA. They may act either as oncogenes or tumor suppressor genes, thus regulating carcinogenesis and tumor progression. The scope of the present study is10to detect and quantitate the expression of miR-10b, miR-19a, miR-20a, miR-126 and miR-155,which regulate the interaction between cancer cells and the immune system during immunosurveillance and immune evasion in the plasma of patients with early and metastatic BC, and associate their expression with clinical outcome, with the ultimate goal of finding patients who are at high risk of relapse and would potentially benefit from additional therapeuticinterventions.2.Patients and Methods Two hundred and fifteen patients with early breast cancer who underwent surgery followed by adjuvant therapy at the Pathological Oncology Department of Heraklion University Hospital(Crete, Greece) between 2004 and 2011 participated in this study, and available plasma from the clinic records was used. Blood was collected after surgery and before the administration of adjuvant therapy. In addition, 74 patients with metastatic breast cancer (mBC) who underwent first-line chemotherapy during the same period at our institution were included. Plasma samples were obtained before starting first-line chemotherapy. 20 healthy donors participated as a control group. Total RNA was isolated using Trizol LS (Ambion Life Technologies). Quantitative real-time PCR was performed using the TaqMan miRNA Reverse Transcription kit and specific miRNA stem-loop primers. The mean expression levels for each miRNA were calculated by the 2-ΔCt method relative to the mean U6 RNA levels. Patients with miRNA expression levels equal toor above the median value were characterized as having high expression, while patients with miRNA expression levels below the median value were characterized as having low expression. The relationship between circulating miRNA expression levels and disease-free survival (DFS) oroverall survival (OS) was assessed using the Kaplan-Meier method, the log rank test (Mantel-Cox)and Cox proportional hazard regression models. To estimate the value of circulating miRNAs in predicting recurrence, ROC (receiver 8 operating characteristics) curves were constructed and the area under the curve (AUC) was calculated.113. Results: Plasma samples from 140 patients with early KM, 64 patients with metastatic KM and 20 healthy women were used for this analysis. After a median follow-up of 108.3 months, 94 patients remained disease-free and 46 of 140 patients relapsed. In patients with metastatic MS, 45 of 64were de novo metastatic and 19 were relapsed patients. Also, 31 patients had triple negative breast cancer. Demographic and clinical characteristics were similar between patients who did not relapse and those who relapsed, with the exception of the percentage of patients with tumors> 5 cm (T3), 4 or more infiltrated axillary lymph nodes, and differentiation grade III being higher in patients with relapse (p= 0.031, p < 0.001 and p=0.034 respectively).The expression levels of the 5 miRNAs were compared between patients: (i) who relapsed (n=46)and those who remained relapse-free during the entire follow-up period (n=94), (ii) with early relapse, defined as recurrence within 2 years after surgery (n=16) and those who relapsed after 2years (n=30) (iii) with late recurrence, defined as recurrence at least 5 years after surgery (n=17)and those who remained free of recurrence (n=94) (iv) with early breast cancer and metastatic breast cancer patients. Only miR-155 expression was lower in patients compared to healthy women (p = 0.023), while miR-155 and miR-10b were lower in relapsed patients compared to healthy women (p = 0.039 and p = 0.002 , respectively). MiR-155 expression in association with axillary lymph node infiltration and tumor differentiation grade demonstrated increased ability to discriminate patients who relapsed from those who remained disease-free [(area under the curve,(AUC = 0.861; p < 0.001)] . Combination of miR-19a and miR-20a expression had the highest performance in discriminating patients with early relapse (AUC = 0.816, p < 0.001). Finally, miR-10b combined with lymph node infiltration and tumor differentiation grade had the highest accuracy in discriminating patients with late recurrence (AUC = 0.971, p < 0.001). We revealed a124-miRNA panel consisting of miR-19a, miR-20a, miR-126 and miR-155 capable of distinguishing early BC from metastatic BC patients with an AUC of 0.802 (p < 0.001).Survival analysis in patients with early BC revealed that low miR-10b and miR-155 expression was associated with shorter disease-free survival (DFS, p = 0.012 and p = 0.04, respectively) compared with high expression. In addition, miR-126 expression was associated with shorter overall survival(OS; p = 0.045). In multivariate analysis, the number of infiltrated axillary lymph nodes and lowmiR-10b expression independently predicted for shorter DFS (HR: 2.538; p = 0.002 and HR: 1.943;p = 0.033, respectively), while infiltrated axillary lymph nodes with low miR-126 shorter OS (HR:3.537, p = 0.001 and HR: 2.558, p = 0.018). In the subgroup of patients with triple-negative breast cancer (TNBC), low miR-155 expression independently predicted shorter DFS (HR: 5.056, p =0.037). Accordingly, patients with metastatic BC, who had low miR-10b expression, had shorter DFS and OS compared to those with high expression (p = 0.0017 and p = 0.042, respectively). In multivariate analysis, recurrent disease and low miR-10b expression independently predicted shorter PFS (HR: 2.657; p = 0.001 and HR: 1.920; p = 0.017, respectively).4. Conclusion: Our results show that the expression of specific miRNAs involved in the immune response in plasma can predict disease relapse in early BC patients’ years before clinical detection. The successful incorporation of the investigated miRNAs into clinical practice as non-invasive circulating biomarkers could improve patient prognosis as an attempt to address the significant challenge of upscaling or de-escalating therapy according to the risk of recurrence in breast cancer patients. However, due to the small sample of patients and the multiple roles of miRNAs, this merits further evaluation in larger cohorts of patients.

Degree

thesis:*
Grantor dc:publisher
University of Crete (UOC)
Year dc:date
2024

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Thomopoulou, Konstantina
  • Θωμοπούλου, Κωνσταντίνα

Subjects

dc:subject × 16

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/57779

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Thomopoulou, Konstantina; Θωμοπούλου, Κωνσταντίνα. Ο ρόλος των miRNAs που ενέχονται στη ρύθμιση της ανοσολογικής απάντησης στην εκτίμηση της έκβασης ασθενών με καρκίνο μαστού. University of Crete (UOC), 2024. http://hdl.handle.net/10442/hedi/57779